|Bid||4.1500 x 1100|
|Ask||4.1600 x 800|
|Day's Range||4.0500 - 5.2000|
|52 Week Range||2.0000 - 9.2400|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a world-leading, international regulatory and clinical contract research organization (CRO). CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients. In addition, JAN101 is expected to enter Phase 2b trials in early 2021 to treat Peripheral Artery Disease (PAD).
JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its current and future clinical trials, Indications for a New Drug, clinical and research studies planned to be conducted in the future.
JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with non-addictive pain-relieving properties has added two members to its impressive scientific advisory board. John Cooke, MD, PhD will contribute his esteemed depth of vascular expertise to help guide the success of our clinical therapeutic for the treatment of PAD. Alan Kaye, MD, PhD, is an internationally renowned anesthesiologist and pharmacologist whose pain management research and clinical formulation expertise will play a critical role in advancing our efforts to bring non-addictive pain solutions to market.